source
- Roivant's mosliciguat shows strong efficacy in Phase 2 PH-ILD trialRoivant's experimental drug mosliciguat achieved strong efficacy signals in a Phase 2 study of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The mid-stage trial met its…
- AstraZeneca's COPD drug cuts flare-ups in late-stage trials, offering new option for patientsIn two late-stage studies, an AstraZeneca therapy showed a statistically significant reduction in acute exacerbations that worsen chronic obstructive pulmonary disease. The data, released on Tuesda…